2024-09-25 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis

**Company Overview:** Pfizer Inc. is a multinational pharmaceutical corporation that develops and manufactures medicines and vaccines.

**1. Performance vs. S&P 500:**

* **Cumulative Return (PFE):** -11.44%
* **Cumulative Return (VOO):** 133.37%
* **Performance Gap:** -144.81% 
* **Relative Divergence:** 0.0 (This indicates that the stock is currently at the bottom of its historical performance range compared to the S&P 500.)

**2. Recent Price Movements:**

* **Closing Price:** 29.35
* **5-Day Moving Average:** 29.52
* **20-Day Moving Average:** 29.18
* **60-Day Moving Average:** 29.18
* **Analysis:** The stock price is currently trading slightly below its 5-day moving average, indicating potential short-term downward pressure. The 20-day and 60-day moving averages are close to the current price, suggesting a neutral trend.

**3. Technical Indicators:**

* **RSI:** 62.95
* **PPO:** 0.06
* **Delta_Previous_Relative_Divergence:** -1.92 (Indicating a short-term downward trend)
* **Expected_Return:** 0.0% (Maximum 5-year expected return based on current investment amount)

**4. Recent Earnings & Outlook:**

| Date | EPS | Estimated EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

**Analysis:** Pfizer has consistently surpassed earnings expectations in recent quarters. The most recent earnings report for Q2 2024 showed an EPS of $0.6, exceeding the estimated EPS of $0.458. This positive trend suggests that Pfizer continues to perform well despite macroeconomic challenges.

**5. News & Recent Issues:**

**Recent Market Outlook:** Pfizer's stock price has been relatively stable in recent months, but it is facing headwinds from concerns about slowing COVID-19 vaccine demand and generic competition for its blockbuster drug, Paxlovid.

**Analyst Opinions & Performance Highlights:**  According to FINBOLD, the majority of analysts have a "Hold" rating on Pfizer's stock. Some analysts believe the stock is undervalued and has upside potential, while others are concerned about future growth prospects due to the factors mentioned above.

**6. Comprehensive Analysis:**

Pfizer's stock performance has lagged the broader market significantly in recent years. However, the company continues to demonstrate strong financial performance, exceeding earnings expectations consistently.  The stock is currently trading in a neutral range, with short-term downward pressure indicated by technical indicators. Potential future challenges include declining COVID-19 vaccine demand and competition from generic drug manufacturers.

**7. Report:**

Pfizer Inc. (PFE) is a pharmaceutical giant that has struggled to keep pace with the broader market in recent years. Although the company has consistently exceeded earnings expectations, its stock price has been impacted by concerns about slowing COVID-19 vaccine demand and the potential for generic competition for its blockbuster drug, Paxlovid. 

Technically, the stock is currently trading slightly below its 5-day moving average, suggesting potential short-term downward pressure. However, the 20-day and 60-day moving averages are close to the current price, indicating a neutral trend overall. 

Despite these headwinds, Pfizer's strong earnings performance suggests continued growth and a potentially undervalued stock. Investors should closely monitor the company's future earnings reports and developments related to COVID-19 vaccine demand and generic drug competition for a more informed investment decision. 
